Our Publications
Peer Reviewed (recent selected)
2025
Aldafas R, Vinogradova Y, Crabtree TSJ, Gordon J, Idris I. The legacy effect of early HbA1c control on microvascular complications and hospital admissions in type 2 diabetes: findings from a large UK study. Ther Adv Endocrinol Metab. 2025 Jun 20;16:20420188251350897. doi: 10.1177/20420188251350897. PMID: 40547904; PMCID: PMC12181706.
Griffiths AD, Young RO, Yuan Y, Chaudhary MA, Lee A, Gordon J, McEwan P. Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data. Pharmacoecon Open. 2025 Mar;9(2):247-257. doi: 10.1007/s41669-024-00545-z. Epub 2024 Dec 6. PMID: 39641881; PMCID: PMC11865396.
Taie A, Gheorghe M, Amos J, Morton A, Gordon J, Jenkins NC, Padgett TE, Hollinghurst J, Taylor G. Antimicrobial resistance trends, predictors, and burden in England: a retrospective study using the Clinical Practice Research Datalink from 2015 to 2021. Int J Antimicrob Agents. 2025 May 13;66(3):107535. doi: 10.1016/j.ijantimicag.2025.107535. Epub ahead of print. PMID: 40374082.
2024
Yang W, Zhen X, Sun X, Khatiwada SU, Yang D, Chen Y, Dong P, Al-Taie A, Gordon J, Dong H. Estimating the value of new antibiotic treatment strategies in Zhejiang province, China: cost-effectiveness analysis based on a validated dynamic model. BMJ Open. 2024 Aug 29;14(8):e086039. doi: 10.1136/bmjopen-2024-086039. PMID: 39209783; PMCID: PMC11367305.
Pollock KG, Dickerson C, Kainth M, Lawton S, Hurst M, Sugrue DM, Arden C, Davies DW, Martin AC, Sandler B, Gordon J, Farooqui U, Clifton D, Mallen C, Rogers J, Hill NR, Camm AJ, Cohen AT. Undertaking multi-centre randomised controlled trials in primary care: learnings and recommendations from the PULsE-AI trial researchers. BMC Prim Care. 2024 Jan 2;25(1):7. doi: 10.1186/s12875-023-02246-8. PMID: 38166641; PMCID: PMC10759575.
Gordon J, Gheorghe M, Harrison C, Miller R, Dennis J, Steuten L, Goldenberg S, Gandra S, Al-Taie A. Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study. Pharmacoeconomics. 2024 Mar;42(3):329-341. doi: 10.1007/s40273-023-01337-9. Epub 2023 Nov 24. PMID: 38001394; PMCID: PMC10861689.
Sugai M, Yuasa A, Miller RL, Vasilopoulos V, Kurosu H, Taie A, Gordon JP, Matsumoto T. Correction to: An Economic Evaluation Estimating the Clinical and Economic Burden of Increased Vancomycin-Resistant Enterococcus faecium Infection Incidence in Japan. Infect Dis Ther. 2023 Aug;12(8):2191-2192. doi: 10.1007/s40121-023-00853-7. Erratum for: Infect Dis Ther. 2023 Jun;12(6):1695-1713. doi: 10.1007/s40121-023-00826-w. PMID: 37635180; PMCID: PMC10505112.
2023
Gordon J, Gheorghe M, Goldenberg S, Miller R, Dennis J, Al-Taie A. Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom. Pharmacoeconomics. 2023 Dec;41(12):1657-1673. doi: 10.1007/s40273-023-01310-6. Epub 2023 Aug 16. PMID: 37587392; PMCID: PMC10635959.
Barmpouni M, Gordon JP, Miller RL, Dennis JW, Grammelis V, Rousakis A, Souliotis K, Poulakou G, Daikos GL, Al-Taie A. Clinical and Economic Value of Reducing Antimicrobial Resistance in the Management of Hospital-Acquired Infections with Limited Treatment Options in Greece. Infect Dis Ther. 2023 Jul;12(7):1891-1905. doi: 10.1007/s40121-023-00837-7. Epub 2023 Jul 6. PMID: 37410343; PMCID: PMC10390381.
Gordon JP, Al Taie A, Miller RL, Dennis JW, Blaskovich MAT, Iredell JR, Turnidge JD, Coombs GW, Grolman DC, Youssef J. Quantifying the Economic and Clinical Value of Reducing Antimicrobial Resistance in Gram-negative Pathogens Causing Hospital-Acquired Infections in Australia. Infect Dis Ther. 2023 Jul;12(7):1875-1889. doi: 10.1007/s40121-023-00835-9. Epub 2023 Jun 21. PMID: 37341866; PMCID: PMC10390426.
Sugai M, Yuasa A, Miller RL, Vasilopoulos V, Kurosu H, Taie A, Gordon JP, Matsumoto T. An Economic Evaluation Estimating the Clinical and Economic Burden of Increased Vancomycin-Resistant Enterococcus faecium Infection Incidence in Japan. Infect Dis Ther. 2023 Jun;12(6):1695-1713. doi: 10.1007/s40121-023-00826-w. Epub 2023 Jun 11. Erratum in: Infect Dis Ther. 2023 Aug;12(8):2191-2192. doi: 10.1007/s40121-023-00853-7. PMID: 37302137; PMCID: PMC10281932.
Zannad F, Alikhaani J, Alikhaani S, Butler J, Gordon J, Jensen K, Khatib R, Mantovani L, Martinez R, Moore WF, Murakami M, Roessig L, Stockbridge N, Van Spall HGC, Yancy C, Spertus JA. Patient-reported outcome measures and patient engagement in heart failure clinical trials: multi-stakeholder perspectives. Eur J Heart Fail. 2023 Apr;25(4):478-487. doi: 10.1002/ejhf.2828. Epub 2023 Mar 22. PMID: 36924142.
Aldafas R, Crabtree T, Vinogradova Y, Gordon JP, Idris I. Efficacy and safety of intensive versus conventional glucose targets in people with type 2 diabetes: a systematic review and meta-analysis. Expert Rev Endocrinol Metab. 2023 Jan;18(1):95-110. doi: 10.1080/17446651.2023.2166489. Epub 2023 Jan 31. PMID: 36718676.
2022
Hill NR, Groves L, Dickerson C, Ochs A, Pang D, Lawton S, Hurst M, Pollock KG, Sugrue DM, Tsang C, Arden C, Wyn Davies D, Martin AC, Sandler B, Gordon J, Farooqui U, Clifton D, Mallen C, Rogers J, Camm AJ, Cohen AT. Identification of undiagnosed atrial fibrillation using a machine learning risk-prediction algorithm and diagnostic testing (PULsE-AI) in primary care: a multi-centre randomized controlled trial in England. Eur Heart J Digit Health. 2022 Mar 23;3(2):195-204. doi: 10.1093/ehjdh/ztac009. PMID: 36713002; PMCID: PMC9707963.
Barmpouni M, Gordon JP, Miller RL, Pritchard CRJ, Dennis JW, Grammelis V, Rousakis A, Souliotis K, Poulakou G, Daikos GL, Al-Taie A. Estimating the Clinical and Economic Impact of Introducing a New Antibacterial into Greek Clinical Practice for the Management of Hospital-Acquired Infections with Limited Treatment Options. Infect Dis Ther. 2023 Feb;12(2):527-543. doi: 10.1007/s40121-022-00743-4. Epub 2022 Dec 21. PMID: 36544074; PMCID: PMC9770558.
Matsumoto T, Yuasa A, Miller R, Pritchard C, Ohashi T, Taie A, Gordon J. Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling Study. Pharmacoecon Open. 2023 Jan;7(1):65-76. doi: 10.1007/s41669-022-00368-w. Epub 2022 Sep 15. PMID: 36107306; PMCID: PMC9476387.
Hill NR, Groves L, Dickerson C, Boyce R, Lawton S, Hurst M, Pollock KG, Sugrue DM, Lister S, Arden C, Davies DW, Martin AC, Sandler B, Gordon J, Farooqui U, Clifton D, Mallen C, Rogers J, Camm AJ, Cohen AT. Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomized controlled trial in England. J Med Econ. 2022 Jan-Dec;25(1):974-983. doi: 10.1080/13696998.2022.2102355. PMID: 35834373.
Crabtree T, Ogendo JJ, Vinogradova Y, Gordon J, Idris I. Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies.Expert Rev Endocrinol Metab. 2022 May;17(3):255-267. doi: 10.1080/17446651.2022.2079495. Epub 2022 May 25. PMID: 35614863.
2021
Matsumoto T, Darlington O, Miller R, Gordon J, McEwan P, Ohashi T, Taie A, Yuasa A. Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan. J Health Econ Outcomes Res. 2021 Oct 6;8(2):64-75. doi: 10.36469/001c.28327. PMID: 34703834; PMCID: PMC8494726.
Gordon J, Stainthorpe A, Jones B, Jacob I, Hertel N, Diaz J, Yuan Y, Borrill J. Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making. Pharmacoecon Open. 2021 Dec;5(4):701-713. doi: 10.1007/s41669-021-00279-2. Epub 2021 Jul 2. PMID: 34216002; PMCID: PMC8611140.
Sekelj S, Sandler B, Johnston E, Pollock KG, Hill NR, Gordon J, Tsang C, Khan S, Ng FS, Farooqui U. Detecting undiagnosed atrial fibrillation in UK primary care: Validation of a machine learning prediction algorithm in a retrospective cohort study. Eur J Prev Cardiol. 2021 May 22;28(6):598-605. doi: 10.1177/2047487320942338. PMID: 34021576.
2020
Hill NR, Arden C, Beresford-Hulme L, Camm AJ, Clifton D, Davies DW, Farooqui U, Gordon J, Groves L, Hurst M, Lawton S, Lister S, Mallen C, Martin AC, McEwan P, Pollock KG, Rogers J, Sandler B, Sugrue DM, Cohen AT. Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial. Contemp Clin Trials. 2020 Dec;99:106191. doi: 10.1016/j.cct.2020.106191. Epub 2020 Oct 19. PMID: 33091585; PMCID: PMC7571442.
Sekelj S, Sandler B, Johnston E, Pollock KG, Hill NR, Gordon J, Tsang C, Khan S, Ng FS, Farooqui U. Detecting undiagnosed atrial fibrillation in UK primary care: Validation of a machine learning prediction algorithm in a retrospective cohort study. Eur J Prev Cardiol. 2020 Aug 13:2047487320942338. doi: 10.1177/2047487320942338. Epub ahead of print. PMID: 32787456.
Hawkins R, Fife K, Hurst M, Wang M, Naicker N, Nolasco S, Eisen T, Matakidou A, Gordon J. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.BMC Cancer. 2020 Jul 17;20(1):670. doi: 10.1186/s12885-020-07154-z. PMID: 32680483; PMCID: PMC7368711.
Gordon J, Danne T, Beresford-Hulme L, Bennet H, Tank A, Edmonds C, Thorén F, Scheerer MF, McEwan P. Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme. Diabetes Ther. 2020 May;11(5):1135-1146. doi: 10.1007/s13300-020-00807-z. Epub 2020 Apr 9. PMID: 32274678; PMCID: PMC7192983.
Gordon J, Darlington O, McEwan P, Lumley M, Taie A, Hicks M, Charbonneau C, Blake A, Hawkins N, Goldenberg S, Otter J, Wilcox M. Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model. Pharmacoeconomics. 2020 Aug;38(8):857-869. doi: 10.1007/s40273-020-00906-6. PMID: 32249396.
Gordon J, Beresford-Hulme L, Bennett H, Tank A, Edmonds C, McEwan P. Relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: Observations from the DEPICT clinical trial programme. Diabetes Obes Metab. 2020 May;22(5):857-865. doi: 10.1111/dom.13972. Epub 2020 Feb 21. PMID: 31970881.
Hill NR, Sandler B, Mokgokong R, Lister S, Ward T, Boyce R, Farooqui U, Gordon J. Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: evaluation of a machine learning risk prediction algorithm. J Med Econ. 2020 Apr;23(4):386-393. doi: 10.1080/13696998.2019.1706543. Epub 2020 Jan 10. PMID: 31855091.
2019
Hill NR, Ayoubkhani D, McEwan P, Sugrue DM, Farooqui U, Lister S, Lumley M, Bakhai A, Cohen AT, O’Neill M, Clifton D, Gordon J. Predicting atrial fibrillation in primary care using machine learning. PLoS One. 2019 Nov 1;14(11):e0224582. doi: 10.1371/journal.pone.0224582. PMID: 31675367; PMCID: PMC6824570.
Lacoin L, Hurst M, Hill NR, Gordon J, Geretti AM, Aspinall R, Corless L, Gao-Du Y, Mistry L, Mutimer D. Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis. BMJ Open. 2019 Aug 5;9(8):e029066. doi: 10.1136/bmjopen-2019-029066. PMID: 31383704; PMCID: PMC6687009.
Presentations and Conference Proceedings
Young R, Yuan Y, Chaudhary MA, Lee A, Gordon J, McEwan P. When Should I Mix? Improving Understanding of the Predictive Behavior of Mixture-Cure Survival Models Informed by Immature Data. 2023-11, ISPOR Europe 2023, Copenhagen, Denmark. Value in Health, Volume 26, Issue 11, S2 (December 2023)
R Young, C Pritchard, Y Yuan, M Chaudhary, A Lee, J Gordon, P McEwan. MSR16 Mixture-Cure Modelling of Overall Survival of Patients With Metastatic Non-Small Cell Lung Cancer Receiving Nivolumab + Ipilimumab in CheckMate 277 – Updated With 5 Years of Follow-up. Value in Health, Volume 25, Issue 12, Supplement, 2022, Page S353. ISSN 1098-3015.
A Griffiths, R Young, Y Yuan, M Chaudhary, A Lee, J Gordon, P McEwan,. E513 Health Economic Evaluation Incorporating Mixture Cure Survival Analysis of Nivolumab Plus Ipilimumab for Previously Untreated Metastatic NSCLC. Value in Health, Volume 25, Issue 12, Supplement, 2022, Page S156. ISSN 1098-3015. https://doi.org/10.1016/j.jval.2022.09.755.
R Young, C Pritchard, Y Yuan, M Chaudhary, A Lee, J Gordon, P McEwan. MSR68 Mixture-Cure Modelling of the Overall Survival Outcomes of Patients with Advanced Non-Small Cell Lung Cancer (ANSCLC) Receiving Nivolumab + Ipilimumab in CheckMate-227. Value in Health, Volume 25, Issue 7, Supplement, 2022, Page S531. ISSN 1098-3015. https://doi.org/10.1016/j.jval.2022.04.1275.
NR Hill, L Groves, C Dickerson, A Ochs, S Lawton, M Hurst, KG Pollock, D Sugrue, C Tsang, C Arden, DW Davies, AC Martin, B Sandler, J Gordon, U Farooqui, D Clifton, C Mallen, J Rogers, JA Camm, A Cohen. POSC125 Identification of Undiagnosed Atrial Fibrillation Using a Machine Learning Risk Prediction Algorithm and Diagnostic Testing (PULSE-AI) in Primary Care: Health Economic Impact Assessment of a UK Randomised Controlled Trial. Value in Health, Volume 25, Issue 1, Supplement, 2022, Page S111, ISSN 1098-3015. https://doi.org/10.1016/j.jval.2021.11.529.
Brownrigg et al. Clinical profiles and incident heart failure in cardiomyopathies: a population-based linked electronic health record cohort study. ESC Congress 2020
Alikhan et al. Apixaban versus Heparin/Warfarin Treatment in Pulmonary Embolism: Results from the UK Apixaban Length-of-Stay Pulmonary Embolism – Hospital Admissions Study (ALPHA-PE). International Society on Thrombosis and Haematosis 2020.
Henning et al. Change in disease activity and treatment response after abatacept treatment for rheumatoid arthritis: real-world evidence from the UK. Annals of the Rheumatic Diseases 2020;79:1446-1447.
Ryan et al. Time on treatment and treatment patterns in patients with metastatic colorectal carcinoma: a retrospective chart review. NCRI 2020
Jacob, A. van Doornewaard, S. Sadler, M. Radford, M. Gharaibeh, J. Gordon, X. L.U. PMS15 Estimating the Budget IMPACT of the Introduction of Filgotinib for the Treatment of Rheumatoid Arthritis in the UK. Value in Health, Volume 23, Supplement 2, 2020, Pages S594-S595. ISSN 1098-3015. https://doi.org/10.1016/j.jval.2020.08.1146.
Jacob, L. Beresford, K. Butler, B. McNamara, J. Dennis, O. Hayward, M. Turner, S. Sadler, D. Sugrue, J. Gordon, M. Radford, M. Gharaibeh, X. L.U. PMS5 Comparative Efficacy of Filgotinib Versus Alternative Treatments for Rheumatoid Arthritis in Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: A Systematic Review and Network Meta-Analysis. Value in Health, Volume 23, Supplement 2, 2020, Pages S592-S593. ISSN 1098-3015. https://doi.org/10.1016/j.jval.2020.08.1136
Lu, M. Radford, M. Gharaibeh, P. Gabb, A. Hewins, J. Dennis, M. Turner, T. Edwards, S. Sadler, D. Sugrue, I. Jacob, J. Gordon. PMS16 Cost Effectiveness in Rheumatoid Arthritis: A Systematic Literature Review. Value in Health, Volume 23, Supplement 2, 2020, Page S595. ISSN 1098-3015. https://doi.org/10.1016/j.jval.2020.08.1147.
Gordon, M. Norman, M. Hurst, T. Mason, C. Dickerson, B. Sandler, K.G. Pollock, U. Farooqui, D. Clifton, L. Groves, C. Tsang, A. Bakhai, N.R. Hill. PCV93 Using Machine Learning to Predict Anticoagulation Control in Atrial Fibrillation: A UK Retrospective Database Study. Value in Health, Volume 23, Supplement 2, 2020, Page S503. ISSN 1098-3015. https://doi.org/10.1016/j.jval.2020.08.584.
I. Jacob, L. Beresford-Hulme, K. Butler, B. McNamara, J. Dennis, J. Baker, O. Hayward, S. Sadler, D. Sugrue, J. Gordon, M. Radford, M. Gharaibeh, X. L.U. PMS4 Comparative Efficacy of Filgotinib Versus Alternative Treatments for Rheumatoid Arthritis in Patients with an Inadequate Response to Methotrexate: A Systematic Review and Network Meta-Analysis. Value in Health, Volume 23, Supplement 2, 2020, Page S592. ISSN 1098-3015. https://doi.org/10.1016/j.jval.2020.08.1135.
Sadler, I. Jacob, O. Darlington, E. Still, J. Gordon, M. Radford, M. Gharaibeh,. PMS19 Validation of a Cost-Effectiveness MODEL in Rheumatoid Arthritis. Value in Health, Volume 23, Supplement 2, 2020, Page S595. ISSN 1098-3015. https://doi.org/10.1016/j.jval.2020.08.1150.
Jacob, K. Badora, A. Hewins, N. Nour, J. Gordon. PNS66 Non-inferiority trials in health technology assessment – do they necessitate a cost-minimisation approach? Value in Health, Volume 22, Supplement 3, 2019, Page S773. ISSN 1098-3015, https://doi.org/10.1016/j.jval.2019.09.1968.
Gordon et al. The impact of adjunct dapagliflozin on treatment satisfaction in type 1 diabetes mellitus. ISPOR 2019
Hill et al. Cost-effectiveness of targeted screening using a machine learning risk prediction tool for the identification of patients with atrial fibrillation. ISPOR 2019
Young R, Jones B, Harrison J, Ward T, Pang H, Tyas D, McEwan P, Gordon J. Nivolumab monotherapy for patients with relapsed or refractory classical Hodgkin lymphoma following autologous hematopoietic cell transplantation and brentuximab vedotin: systematic literature review and matching-adjusted indirect comparison. British Society for Haematology – 58th Annual Scientific Meeting, Liverpool 2018.
R Hawkins, K Fife, M Hurst, J Gordon, N Naicker, M Wang. Estimating real-world health outcomes in patients with advanced or metastatic renal cell carcinoma (mRCC) treated with targeted systemic therapy. EICKS 2018.
Hill N, Ayoubkhani D, Lumley M, Lister S, Farooqui U, McEwan P, Gordon J, O’Neil M, Clifton D. Incorporating Time-Varying Clinical Data Into a Machine Learning Algorithm to Detect Atrial Fibrillation and Flutter. International Society for Pharmacoepidemiology (ICPE), Prague 2018.
Gordon et al. Nivolumab is predicted to have improved clinical outcomes over best supportive care in a western population of pre-treated gastric cancer patients; an indirect treatment comparison analysis. ISPOR EU, 2018.
Gordon et al. Validation and Conceptual Design of a Health Economic Model for Anaemia in Myelodysplastic Syndrome. ISPOR EU, 2018.Gordon et al. Prescribing choice and the cost of anticoagulation in AF: a real-world study comparing healthcare expenditure with warfarin and apixaban. ISPOR EU, 2018.
Gordon et al. A Health Economic Model for Myelodysplastic Syndrome: Systematic Literature Review to Inform Conceptual Model Design. ISPOR US, Baltimore 2018.
Gordon et al. Economic modelling of chronic kidney disease: a systematic literature review to inform conceptual model design. ISPOR US, Baltimore 2018.
Gordon et al. Defining and estimating the cure fraction bias in survival modelling of novel immuno-oncology therapy agents in small-cell lung cancer. ISPOR US, Baltimore 2018.
Machine learning to detect and diagnose atrial fibrillation and atrial flutter (AF/F) using routine clinical data.ISPOR US, Baltimore 2018.
Gordon J, McEwan P, Puelles J. 1333-P – Economic Evaluation of Triple Therapy with Aloglipin, Metformin and Sulfonylurea. American Diabetes Association; 2017; San Diego.
Jones B, Ward T, Harrison J, Hurst M, Tyas D, McEwan P, Gordon J. PCN120 – The Cost-effectiveness of Nivolumab for the Treatment of People with Relapsed or Refractory Classical Hodgkins Lymphoma Following Autologous Stem Cell Transplant and Brentuximab Vedotin. ISPOR, EU;2017; Glasgow.
Ward T, Jones B, Harrison JP, Hurst M, Tyas D, McEwan P, Gordon J. PCN 118 – The Clinical Cost Effectiveness of Dasatinib Versus Nilotinib for the First and Second Line Treatment of People with Chronic Myeloid Leukaemia. ISPOR, EU; 2017; Glasgow.
H Bennett, E Palaka, D Ayoubkhani, M Evans, J Gordon, K Kim, P McEwan. Impact of End-Stage Renal Disease on Health Economic Outcomes of Hyperkalaemia Management In Patients With Chronic Kidney Disease. ISPOR, EU; 2017; Glasgow.
T Ward, J Gordon, H Bennett Wilton, S Medland, P McEwan. Contrasting Improving Rates of Cancer Survival In The Context of Life Years Lost Compared To The General Population. ISPOR, EU; 2017; Glasgow.
Ward T, Gordon J, Wygant G, Yan J, Wang F, McEwan P. Assessing the economic impact of the introduction of daclatasvir in combination with asunaprevir for the treatment of chronic hepatitis C in China. 2017-11, ISPOR Europe 2017, Glasgow, Scotland. Value in Health, Vol. 20, No. 9 (October 2017)
Puelles J, Gordon J, McEwan P, Evans M, Sinclair A. 1139 – Interrelationship between treatment choice, glycaemic control and event incidence: optimal management of glycaemia in older patients with type 2 diabetes. EASD; 2016; Munich
McEwan P, Gordon J, Ward T, Penrod JR, Yuan Y. PRM83 – Empirical Assessment of the Impact of Model Choice (Markov State Transition vs Partitioned Survival) in Modeling Small Cell Lung Cancer. ISPOR, EU; 2016; Vienna
McEwan P, Gordon J, Foos V, Lamotte M, Evans M, Paldanius P. PDB31 – Estimating the cost effectiveness of Vildagliptin versus Sulphonylurea in combination with Metformin: Clinical guidelines versus clinical practice. ISPOR, US; 2016; Washington DC
McEwan P, Gordon J, Foos V, Lamotte M, Evans M, Paldanius P. PDB32 – Cost effectiveness of Type 2 Diabetes treatments in middle eastern countries: an economic evaluation of the EDGE study using patient level data.ISPOR, US; 2016; Washington DC
McEwan P, Gordon J, Bennett H, Bergenheim K, Qin L. PDB58 – Flexibly Modelling HbA1c Progression in Type 2 Diabetes to Estimate the Impact of Clinical Inertia on Costs and Quality-Adjusted Life Years. ISPOR, EU; 2016; Vienna
McEwan P, Fellows J, Yapp R, Bergenheim K, Qin L, Varol N, Bennett H, Gordon J. 1228-P – Modelling HbA1c Trajectory in Patients with Type 2 Diabetes Mellitus (T2DM). American Diabetes Association; 2016; New Orleans
McEwan P, Bennett H, Gordon J, Bolin K, Bergenheim K. PDB59 – Quantifying the Health Economic Value Associated with Unit Changes in HbA1c in Type 1 Diabetes Mellitus. ISPOR, EU; 2016; Vienna
McEwan P, Bennett H, Fellows J, Yapp R, Bergenheim K, Qin L, Varol N, Gordon J. PRM 96 – Alternative approaches to modelling HbA1c progression in type 2 diabetes and their impact on health economic outcomes. ISPOR, US; 2016; Washington DC
Gordon J, McEwan P, Evans M, Puelles J, Sinclair A. 903 – Validating prescribing choice in older patients with type 2 diabetes: an economic analysis of patient outcomes based on real world data. EASD 2016; Munich
Foos V, Gordon J, Evans M, Paldanius P, McEwan P. 899 – Clinical practice and outcomes versus clinical guidelines: a real-world perspective on the updated NICE guidelines. EASD; 2016; Munich
Gordon J, Mcewan PC, Sugrue D, Puelles J. 1369-P – Factors Predictive of Weight Gain and Implications for Diabetes Modelling: A Study in Type 2 Diabetes Patients Initiating Metformin and Sulphonylurea Combination Therapy. American Diabetes Association; 2015; Massacheusetts
McEwan P, Gordon J, Evans M, Puelles J. PDB161 – Factors Associated With Weight Gain and Hypoglycaemia and The Impact Upon Hospitalisation in Type 2 Diabetes Patients Managed With Metformin Plus Sulphonylurea.ISPOR, EU; 2014; Amsterdam
Gordon J, McEwan P, Sabale U, Kartman B. PDB70 – The Cost-Effectiveness of Exenatide Bid Versus Insulin Lispro Tid As Add-On Therapy to Titrated Insulin Glargine in Patients With Type 2 Diabetes–An Analysis From The Swedish Health Care Perspective. ISPOR, EU; 2014; Amsterdam
Gordon J, Bell KF, Shah M, Ward T, Mcewan PC. 1195-P – Importance of Longer-term Follow-up Data in Estimating Cost-Effectiveness of New Treatments for Type 2 Diabetes. American Diabetes Association; 2014; San Francisco
Gordon J, Karnon J. Health technology appraisal of new drugs – are we getting it right? 2011-11, ISPOR Europe 2011, Madrid, Spain. Value in Health, Vol. 14, No. 7 (November 2011)
Lister S, Gordon JP, McEwan P. New quality of life (QOL) data on UK patients with refractory neuropathic pain. 2009-10, ISPOR Europe 2009, Paris, France. Value in Health, Vol. 12, No. 7 (October 2009)